Novartis paid Takeda $3.4 billion for its FDA-approved dry eye drug Xiidra during the Japanese pharma’s merger with Shire in 2019, outlining the sales potential in this market niche. But with ...
Shire’s potential blockbuster Xiidra (lifitegrast) has been approved in the US for dry eye disease, bouncing back from a rejection by the regulator late last year. Xiidra, in a 5% solution ...
Irish Examiner on MSN1d
Losses increase at Bausch + Lomb as revenues climb to $2.2bnUse precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...
Pre-tax losses at the main Irish unit of eye care product firm Bausch + Lomb increased by 4.5% to $959.7m (€925m) in 2023.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback